These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 8585757)

  • 21. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation.
    Lam E; Parkin NT
    Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976
    [No Abstract]   [Full Text] [Related]  

  • 22. Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
    Clemente JC; Hemrajani R; Blum LE; Goodenow MM; Dunn BM
    Biochemistry; 2003 Dec; 42(51):15029-35. PubMed ID: 14690411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based design of symmetric inhibitors of HIV-1 protease.
    Erickson J; Kempf D
    Arch Virol Suppl; 1994; 9():19-29. PubMed ID: 8032250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites.
    Fehér A; Weber IT; Bagossi P; Boross P; Mahalingam B; Louis JM; Copeland TD; Torshin IY; Harrison RW; Tözsér J
    Eur J Biochem; 2002 Aug; 269(16):4114-20. PubMed ID: 12180988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease.
    Kaplan AH; Michael SF; Wehbie RS; Knigge MF; Paul DA; Everitt L; Kempf DJ; Norbeck DW; Erickson JW; Swanstrom R
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5597-601. PubMed ID: 8202533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Appearance of a single amino acid insertion at position 33 in HIV type 1 protease under a lopinavir-containing regimen, associated with reduced protease inhibitor susceptibility.
    Magiorkinis E; Paraskevis D; Detsika MG; Lu L; Magiorkinis G; Lazanas M; Imbrechts S; Van Laethem K; Vandamme AM; Pilot-Matias T; Molla A; Camacho RJ; Hatzakis A
    AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1223-9. PubMed ID: 21417947
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.
    Lefebvre E; Schiffer CA
    AIDS Rev; 2008; 10(3):131-42. PubMed ID: 18820715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases.
    Lin YC; Beck Z; Morris GM; Olson AJ; Elder JH
    J Virol; 2003 Jun; 77(12):6589-600. PubMed ID: 12767979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structures of a multidrug-resistant human immunodeficiency virus type 1 protease reveal an expanded active-site cavity.
    Logsdon BC; Vickrey JF; Martin P; Proteasa G; Koepke JI; Terlecky SR; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    J Virol; 2004 Mar; 78(6):3123-32. PubMed ID: 14990731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO; Batista PR; Costa MG; Dardenne LE; Pascutti PG; Soares MA
    J Mol Graph Model; 2010 Sep; 29(2):137-47. PubMed ID: 20541446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding of Clinical Inhibitors to a Model Precursor of a Rationally Selected Multidrug Resistant HIV-1 Protease Is Significantly Weaker Than That to the Released Mature Enzyme.
    Park JH; Sayer JM; Aniana A; Yu X; Weber IT; Harrison RW; Louis JM
    Biochemistry; 2016 Apr; 55(16):2390-400. PubMed ID: 27039930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors.
    Ntemgwa M; Brenner BG; Oliveira M; Moisi D; Wainberg MA
    Antimicrob Agents Chemother; 2007 Feb; 51(2):604-10. PubMed ID: 17116674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
    BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Wide-open" 1.3 A structure of a multidrug-resistant HIV-1 protease as a drug target.
    Martin P; Vickrey JF; Proteasa G; Jimenez YL; Wawrzak Z; Winters MA; Merigan TC; Kovari LC
    Structure; 2005 Dec; 13(12):1887-95. PubMed ID: 16338417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sequence variability of the HIV type 1 protease gene in thai patients experienced with antiretroviral therapy.
    Nukoolkarn S; Pongthapisith V; Panyim S; Leelamanit W
    AIDS Res Hum Retroviruses; 2004 Dec; 20(12):1368-72. PubMed ID: 15650431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.